SCHEMBL5658513

SCHEMBL5658513

CCOc1cccc(N2C(=O)C(c3cc(C)c(O)c(C)c3)(c3cc(C)c(O)c(C)c3)c3ccccc32)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 3/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CNR1 P21554 1/20 0.40
GPR55 Q9Y2T6 1/20 0.40
ALDH1A1 P00352 4/20 0.38
NOTUM Q6P988 2/20 0.38
BACE1 P56817 1/20 0.35
NSD2 O96028 1/20 0.35
POLB P06746 1/20 0.35
DNMT1 P26358 1/20 0.35
BLM P54132 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
TOP2A P11388 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656443 0.88 MAPT (0.44) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5662112 0.85 MAPT (0.41) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5662233 0.84 HSP90AA1 (0.41) MEN1KMT2AMAPTHSD17B10SMN1; SMN2
SCHEMBL5656731 0.84 MAPT (0.41) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5661100 0.84 MAPT (0.41) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5661596 0.84 CNR1 (0.42) MEN1KMT2AMAPTCNR1GPR55
SCHEMBL30929657 0.84 CNR1 (0.42) MEN1KMT2AMAPTCNR1GPR55
SCHEMBL5660035 0.83 USP2 (0.39) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5658510 0.83 CNR1 (0.46) MEN1KMT2AMAPTSMN1; SMN2CNR1
SCHEMBL5658916 0.83 MAPT (0.40) MEN1KMT2AMAPTSMN1; SMN2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US claimed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-7250442-B2 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY (US) 2007-07-31 US disclosed
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators ELI LILLY AND COMPANY 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054712-A1 Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators NR3C2, NR5A1, NR5A2 MEN1 2928/4885KMT2A 3891/4885MAPT 3588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.